Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ADRA1D | P25100 | 4/20 | 0.35 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.35 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.35 |
| ▸ | HTR1A | P08908 | 3/20 | 0.35 |
| ▸ | G6PD | P11413 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | CCR5 | P51681 | 1/20 | 0.34 |
| ▸ | BCHE | P06276 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28700397 | 1.00 | KMT2A (0.41) | KMT2AMEN1TDP1CD274HTT | |
| SCHEMBL29633507 | 0.83 | MEN1 (0.36) | KMT2AMEN1TDP1CD274HTT | |
| SCHEMBL29633575 | 0.82 | KMT2A (0.47) | KMT2AMEN1TDP1CD274HTT | |
| Hydrochloric Acid SCHEMBL29633621 | 0.81 | KMT2A (0.49) | KMT2AMEN1TDP1CD274HTT | |
| SCHEMBL28936763 | 0.80 | KMT2A (0.42) | KMT2AMEN1TDP1SMN1; SMN2LMNA | |
| SCHEMBL28936767 | 0.80 | KMT2A (0.42) | KMT2AMEN1TDP1SMN1; SMN2LMNA | |
| SCHEMBL24489000 | 0.75 | HTT (0.38) | HTTSMN1; SMN2LMNA | |
| SCHEMBL28706178 | 0.75 | TACR1 (0.37) | KMT2AMEN1TDP1SMN1; SMN2ADRA1D | |
| SCHEMBL28706177 | 0.75 | TACR1 (0.37) | KMT2AMEN1TDP1SMN1; SMN2ADRA1D | |
| SCHEMBL28715431 | 0.75 | HTT (0.38) | HTTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2025-06-24 | — | — | US | disclosed |
| CN-119823001-A | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2025-04-15 | — | — | CN | disclosed |
| CN-114206832-B | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2025-04-04 | — | — | CN | disclosed |
| CN-114206832-A | Urea compounds antagonizing LPA1 receptor | 大正制药株式会社 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12338203-B2 | Urea compound for antagonizing LPA1 receptor | LPAR1, LPAR2, LPAR3 | KMT2A 2533/4885MEN1 2436/4885TDP1 4031/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.